Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
CD123 targeted CAR-NK cells (Chongqing Precision Biotech)
- Development stage
- Unknown
- Lead developer
- Chongqing Precision Biotech Co., Ltd
- Modality
- CAR-NK Cells → Other Engineered Cells → Adoptive Cell Transfer → Cell Therapies, Lymphokine-Activated Killer Cells → Native Immune Cells → Adoptive Cell Transfer → Cell Therapies
- Administration
- Intravenous
01
Overview
CD123 targeted CAR-NK cells (specifically PBC065) is an investigational chimeric antigen receptor natural killer (CAR-NK) cell therapy being developed by Chongqing Precision Biotech. It targets CD123, also known as the interleukin-3 receptor alpha subunit, which is frequently overexpressed in various hematologic malignancies, including acute myeloid leukemia (AML) and blastic plasmacytoid dendritic cell neoplasm (BPDCN). By engineering NK cells to express a CAR specific for CD123, the therapy aims to provide a potent, targeted anti-tumor response while potentially offering a better safety profile and off-the-shelf availability compared to traditional CAR-T cell therapies. It is currently being evaluated in Phase 1/2 clinical trials for relapsed or refractory AML and BPDCN.
- Other names
- CD123 CAR-NK cellsCD-123 CAR-NK cellsCD 123 CAR-NK cells
02
Targets
IL3RA (Interleukin 3 Receptor)
Beyond the preview
Go deeper on CD123 targeted CAR-NK cells (Chongqing Precision Biotech).
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on CD123 targeted CAR-NK cells (Chongqing Precision Biotech).